Rhenium-188 (Re-188) is a high energy β-emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy γ-emission, which could be detected by γ-cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the β-emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.

No abstract

Rhenium-186 (Re-186) is a β-emitting radionuclide. Emitted β-particles have ranges up to 4.5 mm in tissue, capable of delivering high doses to skeletal regions of high Re-186 concentrations while sparing adjacent radiosensitive regions and thus making the irradiation well tolerated for the patient. Along with the β-emissions, γ-rays are emitted having an adequate energy for imaging during therapy and biodistribution assessment for patient-specific dosimetry calculations. The relatively short physical half-life combined with the β-emissions allows the delivery of relatively high activity rate for a short period of time in areas of concentration. This study is a short review concerning the palliative treatment of skeletal metastases using 186Re-HEDP. After presenting the dominant ways of 186Re production, special emphasis is given to dosimetry issues while the effect of palliation therapy can be evaluated through the comparison of the absorbed dose in metastatic lesion relatively to the normal bone region. Accurate dose estimation is required taking into account the anatomic individual difference of each patient. For this purpose a patient specific dosimetric model considering metastatic lesions as spherical nodules is introduced. In order to quantify in a representative way the results of palliation treatment, the concept of therapeutic ratios is analyzed.

We present an improved partial wave analysis of the dominant LSP annihilation channel to a fermion-antifermion pair which avoids the non-relativistic expansion being therefore applicable near thresholds and poles. The method we develop allows of contributions of any partial wave in the total angular momentum J in contrast to partial wave analyses in terms of the orbital angular momentum L of the initial state, which is usually truncated to p-waves, and yields very accurate results. The method is formulated in such a way as to allow easy handling of CP -violating phases residing in supersymmetric parameters. We apply this refined partial wave technique in order to calculate the neutralino relic density in the constrained MSSM (CMSSM) in the presence of CP -violating terms occurring in the Higgs -mixing parameter µ and trilinear A coupling for large tan β. The inclusion of CP -violating phases in µ and A does not upset significantly the picture and the annihilation of the LSP's to a bb, through Higgs exchange, is still the dominant mechanism in obtaining cosmologically acceptable neutralino relic densities in regions far from the stau-coannihilation and the 'focus point'. Significant changes can occur if we allow for phases in the gaugino masses and in particular the gluino mass.

We explore in detail the consequences of the CP-violating phases residing in the supersymmetric and soft SUSY breaking parameters in the approximation that family flavour mixings are ignored. We allow for non-universal boundary conditions and in such a consideration the model is described by twelve independent CP-violating phases and one angle which misaligns the vacuum expectation values (VEVs) of the Higgs scalars. We run two-loop renormalization group equations (RGEs), for all parameters involved, including phases, and we properly treat the minimization conditions using the one-loop effective potential with CPviolating phases included. We show that the two-loop running of phases may induce sizable effects for the electric dipole moments (EDMs) that are absent in the one-loop RGE analysis. Also important corrections to the EDMs are induced by the Higgs VEVs misalignment angle which are sizable in the large tan β region. Scanning the available parameter space we seek regions compatible with accelerator and cosmological data with emphasis on rapid neutralino annihilations through a Higgs resonance. It is shown that large CP-violating phases, as required in Baryogenesis scenarios, can be tuned to obtain agreement with WMAP3 cold dark matter constraints, EDMs and all available accelerator data, in extended regions of the parameter space which may be accessible to LHC.